Review of bosentan in the management of pulmonary arterial hypertension

Gabbay, Eli, Fraser, John and McNeil, Keith (2007) Review of bosentan in the management of pulmonary arterial hypertension. Vascular Health and Risk Management, 3 6: 887-900.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ191270_OA.pdf Full text (open access) application/pdf 2.95MB 2
Author Gabbay, Eli
Fraser, John
McNeil, Keith
Title Review of bosentan in the management of pulmonary arterial hypertension
Journal name Vascular Health and Risk Management   Check publisher's open access policy
ISSN 1176-6344
Publication date 2007-12
Sub-type Article (original research)
Open Access Status File (Publisher version)
Volume 3
Issue 6
Start page 887
End page 900
Total pages 14
Editor Roland Asmar
Publisher Dove Press
Language eng
Subject 11 Medical and Health Sciences
1103 Clinical Sciences
Abstract The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. Data from the pivotal placebo controlled studies and their open labeled extensions as well as long term survival and quality of life data is presented. Data is also presented on the potential benefit of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to guide the reader in monitoring potential increases in alanine and aspartate transaminase levels that may occur with bosentan use and the dose adjustments that are recommended as a result of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part of combination therapy in PAH is examined.
Keyword Bosentan
Pulmonary arterial hypertension
Quality of Life
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 05 Jan 2010, 08:40:03 EST by Ms May Balasaize on behalf of Faculty Of Health Sciences